Glimepiride in Type 2 Diabetes Mellitus Thai Patients
CHAICHARN DEEROCHANA WONG, M.D.*,
AMPHA SUTHUUMROON, M.D.***,
THEP HIMATHONGKAM, M.D.*****,
YUPIN BENJASURATAWONG,M.D.***,
VEERASAK SARINNAPAKORN, M.D.*,
SUNITAYA CHANDRAPRASERT, M.D.**,
APICHA TI VICHA YANRA T, M.D.****,
WANNEE NITIYANANT, M.D.****,
SOMPONGSE SUWANWALAIKORN, M.D.**,
SOMBOON VONGTERAPAK, M.D.*****
Affiliation : * Department of Medicine, Rajavithi Hospital, Bangkok 10400,
** Department of Medicine, Faculty of Medicine, Chulalongkom University, Bangkok 10330,
*** Department of Medicine, Pramongkutklao Hospital, Bangkok 10400,
**** Department of Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok 10700,
***** Theptarin Hospital, Bangkok 10110, Thailand.
AbstractThis study aimed to confirm the efficacy of glimepiride given once daily in the treat-
ment of Thai type 2 diabetic patients and to find out the optimum dosage for Thai patients. The
patients were enrolled at the diabetic clinics of 5 hospitals (Rajavithi, Chulalongkorn, Pramong-
kutklao, Siriraj and Theptarin Hospitals). All patients started glimepiride 1 mg once daily and
escalated to 2, 3, 4 and until 6 mg every 4 weeks if fasting plasma glucose (FPG) exceeded 140
mg/dL. Subjects were 60 females and 29 males with an average age of 52.2 ± 10.0 years. Mean
BMI was 25.5 ± 3.8 kg/m2• Fifty seven patients (64.0%) were drug nai·ve and thirty two patients
(36.0%) had been previously treated with oral hypoglycemic agents. Seventy three per cent of
the drug naive and 37 per cent of the previously treated patients could be controlled with 1-2
mg of glimepiride once daily. At the twelfth week of treatment, mean fasting plasma glucose
decreased from 224.6 to 156.6 mg/dL (30% reduction) and mean HbA1c decreased from 10.0 to
7.5 per cent (25% reduction). At the end of the study 49.4 per cent of the patients had HbA1c
< 7.0 per cent, 21.3 per cent had HbA1c 7.0-8.0 per cent and 29.3 per cent had HbA1c > 8.0
per cent. Adverse events that were probably or possibly related to the drug were reported in 5
patients (5.6% ). Three of them were hypoglycemia and two patients had skin rash. All hypo-
glycemic episodes were mild. Glimepiride was indicated to be safe. There were no clinically sig-
nificant changes in clinical laboratory values, physical examinations and vital signs. In conclu-
sion, glimepiride was efficacious and safe in type 2 diabetes Thai patients and 1-2 mg of gli-
mepiride appeared to be a sufficient dose for most newly diagnosed type 2 diabetic patients.
Keywords : Type 2 Diabetes, Glimepiride, Sulfonylurea, Treatment
All Articles
Download
